Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 01 2022
07 01 2022
Historique:
received:
05
09
2021
accepted:
08
12
2021
entrez:
8
1
2022
pubmed:
9
1
2022
medline:
24
2
2022
Statut:
epublish
Résumé
Multiple myeloma (MM) is a cancer of bone marrow (BM) plasma cells, which is increasingly treatable but still incurable. In 90% of MM patients, severe osteolysis results from pathological interactions between MM cells and the bone microenvironment. Delineating specific molecules and pathways for their role in cancer supportive interactions in the BM is vital for developing new therapies. Very Late Antigen 4 (VLA4, integrin α
Identifiants
pubmed: 34996933
doi: 10.1038/s41598-021-03748-0
pii: 10.1038/s41598-021-03748-0
pmc: PMC8741970
doi:
Substances chimiques
Fluorescent Dyes
0
Integrin alpha4beta1
0
Green Fluorescent Proteins
147336-22-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Subventions
Organisme : NCI NIH HHS
ID : P50 CA094056
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB014855
Pays : United States
Organisme : NIH HHS
ID : R01 CA248493
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211466
Pays : United States
Organisme : NIH HHS
ID : NIH -S10OD027042
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA199092
Pays : United States
Organisme : NIH HHS
ID : S10 OD027042
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA176221
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK056341
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248493
Pays : United States
Organisme : NCI NIH HHS
ID : R42 CA257797
Pays : United States
Organisme : NIH HHS
ID : U54 CA199092
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Howlader, N.N.A., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A. (eds). SEER Cancer Statistics Review, 1975–2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/ , based on November 2020 SEER data submission, posted to the SEER web site, April 2021.
Mina, R. et al. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer J. 10, 40 (2020).
pubmed: 32286263
pmcid: 7156404
doi: 10.1038/s41408-020-0307-4
Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M. & Dimopoulos, M. A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 8, 7 (2018).
pubmed: 29330358
pmcid: 5802524
doi: 10.1038/s41408-017-0037-4
Lentzsch, S., Ehrlich, L. A. & Roodman, G. D. Pathophysiology of multiple myeloma bone disease. Hematol. Oncol. Clin. North Am. 21, 1035–1049 (2007).
pubmed: 17996587
doi: 10.1016/j.hoc.2007.08.009
Terpos, E., Christoulas, D., Gavriatopoulou, M. and Dimopoulos, M.A. Mechanisms of bone destruction in multiple myeloma. Eur. J. Cancer Care (Engl). 2017;26.
Terpos, E., Berenson, J., Cook, R. J., Lipton, A. & Coleman, R. E. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 24, 1043–1049 (2010).
pubmed: 20376081
doi: 10.1038/leu.2010.62
Bhutani, M., Foureau, D. M., Atrash, S., Voorhees, P. M. & Usmani, S. Z. Extramedullary multiple myeloma. Leukemia 34, 1–20 (2020).
pubmed: 31776467
doi: 10.1038/s41375-019-0660-0
Sanz-Rodríguez, F., Ruiz-Velasco, N., Pascual-Salcedo, D. & Teixidó, J. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br. J. Haematol. 107, 825–834 (1999).
pubmed: 10606891
doi: 10.1046/j.1365-2141.1999.01762.x
Luo, B. H., Carman, C. V. & Springer, T. A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 25, 619–647 (2007).
pubmed: 17201681
pmcid: 1952532
doi: 10.1146/annurev.immunol.25.022106.141618
Ley, K., Rivera-Nieves, J., Sandborn, W. J. & Shattil, S. Integrin-based therapeutics: Biological basis, clinical use and new drugs. Nat. Rev. Drug. Discov. 15, 173–183 (2016).
pubmed: 26822833
pmcid: 4890615
doi: 10.1038/nrd.2015.10
Abe, M., Hiura, K., Ozaki, S., Kido, S. & Matsumoto, T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J. Bone. Miner. Metab. 27, 16–23 (2009).
pubmed: 19057841
doi: 10.1007/s00774-008-0012-z
Uchiyama, H., Barut, B. A., Mohrbacher, A. F., Chauhan, D. & Anderson, K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82, 3712–3720 (1993).
pubmed: 8260708
doi: 10.1182/blood.V82.12.3712.3712
Liu, Z. et al. Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells. Sci. Signal. 13, eaay8203 (2020).
pubmed: 32457115
pmcid: 7376968
doi: 10.1126/scisignal.aay8203
Giuliani, N. et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106, 2472–2483 (2005).
pubmed: 15933061
doi: 10.1182/blood-2004-12-4986
Huang, Y. et al. CAM-DR: Mechanisms, Roles and Clinical Application in Tumors. Front Cell Dev Biol. 9, 698047 (2021).
pubmed: 34295898
pmcid: 8290360
doi: 10.3389/fcell.2021.698047
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658–1667 (1999).
pubmed: 10029595
doi: 10.1182/blood.V93.5.1658
Hatano, K. et al. Bortezomib overcomes cell adhesion-mediated drug resistance via down-regulation of VLA-4 expression in multiple myeloma. Blood 112, 1634 (2008).
doi: 10.1182/blood.V112.11.1634.1634
Huang, Y., Wang, Y., Tang, J., Qin, S., Shen, X., He, S. and Ju, S. CAM-DR: Mechanisms, roles and clinical application in tumors. Front. Cell Develop. Biol. 2021;9.
Hatano, K. et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 28, 231–242 (2009).
doi: 10.1038/onc.2008.385
Olson, D. L., Burkly, L. C., Leone, D. R., Dolinski, B. M. & Lobb, R. R. Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer Ther. 4, 91–99 (2005).
pubmed: 15657357
doi: 10.1158/1535-7163.91.4.1
Podar, K. et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br. J. Haematol. 155, 438–448 (2011).
pubmed: 21923653
doi: 10.1111/j.1365-2141.2011.08864.x
Shain, K. H. & Dalton, W. S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): New targets for the prevention of acquired MDR. Mol. Cancer Ther. 1, 69–78 (2001).
pubmed: 12467240
Damiano, J. S. & Dalton, W. S. Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma 38, 71–81 (2000).
pubmed: 10811449
doi: 10.3109/10428190009060320
Fontana, F. et al. VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival. Clin. Cancer Res. 27, 1974–1986 (2021).
pubmed: 33355244
doi: 10.1158/1078-0432.CCR-20-2839
Weissleder, R. A clearer vision for in vivo imaging. Nat. Biotechnol. 19, 316–317 (2001).
pubmed: 11283581
doi: 10.1038/86684
Peng, L. et al. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat. Chem. Biol. 2, 381–389 (2006).
pubmed: 16767086
doi: 10.1038/nchembio798
Soodgupta, D. et al. Very late antigen-4 (alpha(4)beta(1) Integrin) targeted PET imaging of multiple myeloma. PLoS ONE 8, e55841 (2013).
pubmed: 23409060
pmcid: 3568146
doi: 10.1371/journal.pone.0055841
Soodgupta, D. et al. Ex vivo and in vivo evaluation of overexpressed VLA-4 in multiple myeloma using LLP2A imaging agents. J. Nucl. Med. 57, 640–645 (2016).
pubmed: 26742713
doi: 10.2967/jnumed.115.164624
Amend, S. R. et al. Whole genome sequence of multiple myeloma-prone C57BL/KaLwRij mouse strain suggests the origin of disease involves multiple cell types. PLoS ONE 10, 0127828 (2015).
doi: 10.1371/journal.pone.0127828
Veres, A. et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15, 27–30 (2014).
pubmed: 24996167
pmcid: 4082799
doi: 10.1016/j.stem.2014.04.020
Sun, Y., Abdul Aziz, A., Bowles, K. & Rushworth, S. High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Cancer Lett. 412, 37–45 (2018).
pubmed: 29031566
doi: 10.1016/j.canlet.2017.10.005
Zaravinos, A., Kanellou, P., Lambrou, G. I. & Spandidos, D. A. Gene set enrichment analysis of the NF-kappaB/Snail/YY1/RKIP circuitry in multiple myeloma. Tumour Biol. 35, 4987–5005 (2014).
pubmed: 24481661
doi: 10.1007/s13277-014-1659-9
Bai, H. et al. TRPV2-induced Ca(2+)-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma. Cell Commun. Signal. 16, 68 (2018).
pubmed: 30326911
pmcid: 6191893
doi: 10.1186/s12964-018-0280-8
Zhao, C. et al. FOXN3 suppresses the growth and invasion of papillary thyroid cancer through the inactivation of Wnt/beta-catenin pathway. Mol. Cell Endocrinol. 515, 110925 (2020).
pubmed: 32619584
doi: 10.1016/j.mce.2020.110925
van Andel, H., Kocemba, K. A., Spaargaren, M. & Pals, S. T. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia 33, 1063–1075 (2019).
pubmed: 30770859
pmcid: 6756057
doi: 10.1038/s41375-019-0404-1
Kwon, J. H. et al. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin. Cancer Res. 16, 5511–5521 (2010).
pubmed: 20851854
doi: 10.1158/1078-0432.CCR-10-0825
Wang, F., Luo, Y., Zhang, L., Younis, M. and Yuan, L. The LncRNA RP11–301G19.1/miR-582–5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway. Cancer Gene Ther. 2021.
Hose, D. et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96, 87–95 (2011).
pubmed: 20884712
doi: 10.3324/haematol.2010.030296
Borisov, N. et al. Machine learning applicability for classification of PAD/VCD chemotherapy response using 53 multiple myeloma RNA sequencing profiles. Front. Oncol. 11, 652063–652063 (2021).
pubmed: 33937058
pmcid: 8083158
doi: 10.3389/fonc.2021.652063
Lemoine, F. M., Dedhar, S., Lima, G. M. & Eaves, C. J. Transformation-associated alterations in interactions between Pre-B cells and fibronectin. Blood 76, 2311–2320 (1990).
pubmed: 2147863
doi: 10.1182/blood.V76.11.2311.2311
Maes, K. et al. The genetic landscape of 5T models for multiple myeloma. Sci. Rep. 8, 15030 (2018).
pubmed: 30301958
pmcid: 6177465
doi: 10.1038/s41598-018-33396-w
Ramirez, P. et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 114, 1340–1343 (2009).
pubmed: 19571319
pmcid: 2727418
doi: 10.1182/blood-2008-10-184721
Vaandrager, J.-W., Kluin, P. & Schuuring, E. The t(11; 14) (q13; q32) in multiple myeloma cell line KMS12 has Its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene. Blood 89, 349–350 (1997).
pubmed: 8978314
doi: 10.1182/blood.V89.1.349
Chanswangphuwana, C. et al. Ex vivo evaluation of VLA-4 expression in primary human multiple myeloma bone marrow samples and in vivo mobilization of murine multiple myeloma cells with small molecule VLA-4 inhibitors. Blood 128, 2056–2056 (2016).
doi: 10.1182/blood.V128.22.2056.2056
Mori, Y. et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149–2154 (2004).
pubmed: 15138161
doi: 10.1182/blood-2004-01-0236
Terpos, E. et al. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Blood Cancer J. 6, e428–e428 (2016).
pubmed: 27232930
pmcid: 4916305
doi: 10.1038/bcj.2016.37
Banks, R. E. et al. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br. J. Cancer. 68, 122–124 (1993).
pubmed: 7686390
pmcid: 1968321
doi: 10.1038/bjc.1993.298
Luque, R. et al. CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression. Br. J. Haematol. 119, 70–78 (2002).
pubmed: 12358905
doi: 10.1046/j.1365-2141.2002.03792.x
Martínez-Viñambres, E. et al. CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patients. Leukemia 26, 1098–1105 (2012).
pubmed: 22134715
doi: 10.1038/leu.2011.335
Kurata, M., Nakagawa, Y., Yamamoto, K., Suzuki, K. & Kitagawa, M. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma. Am. J. Hematol. 83, 755–757 (2008).
pubmed: 18615555
doi: 10.1002/ajh.21234
Michigami, T. et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96, 1953–1960 (2000).
pubmed: 10961900
doi: 10.1182/blood.V96.5.1953
Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M. & Barille, S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98, 3527–3533 (2001).
pubmed: 11739153
doi: 10.1182/blood.V98.13.3527
Baker, D. E. Natalizumab: Overview of its pharmacology and safety. Rev. Gastroenterol. Disord. 7, 38–46 (2007).
pubmed: 17392628
Hutchinson, M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther. Clin. Risk Manag. 3, 259–268 (2007).
pubmed: 18360634
pmcid: 1936307
doi: 10.2147/tcrm.2007.3.2.259
Khoy, K. et al. Natalizumab in multiple sclerosis treatment: From biological effects to immune monitoring. Front Immunol. 11, 549842 (2020).
pubmed: 33072089
pmcid: 7541830
doi: 10.3389/fimmu.2020.549842
Choi, J. et al. Combined VLA-4–targeted radionuclide therapy and immunotherapy in a mouse model of melanoma. J. Nucl. Med. 59, 1843–1849 (2018).
pubmed: 29959213
pmcid: 6278902
doi: 10.2967/jnumed.118.209510
Cortez, A. et al. Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma. Nucl. Med. Biol. 88–89, 62–72 (2020).
pubmed: 32799049
doi: 10.1016/j.nucmedbio.2020.07.006
Nair-Gupta, P. et al. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment. Blood Cancer J. 10, 65 (2020).
pubmed: 32483120
pmcid: 7264144
doi: 10.1038/s41408-020-0331-4
Bretscher, M. S. Circulating integrins: alpha 5 beta 1, alpha 6 beta 4 and Mac-1, but not alpha 3 beta 1, alpha 4 beta 1 or LFA-1. EMBO J. 11, 405–410 (1992).
pubmed: 1531629
pmcid: 556468
doi: 10.1002/j.1460-2075.1992.tb05068.x
Rainero, E. et al. Ligand-occupied integrin internalization links nutrient signaling to invasive migration. Cell Rep. 10, 398–413 (2015).
pubmed: 25600874
doi: 10.1016/j.celrep.2014.12.037
Runnels, J. M. et al. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J. Biomed. Opt. 16, 011006 (2011).
pubmed: 21280893
pmcid: 3033873
doi: 10.1117/1.3520571
Sun, J. et al. Enhancing in vivo tumor boundary delineation with structured illumination fluorescence molecular imaging and spatial gradient mapping. J. Biomed. Opt. 21, 80502 (2016).
pubmed: 27580364
doi: 10.1117/1.JBO.21.8.080502
Bolzoni, M. et al. IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica 102, 773–784 (2017).
pubmed: 28057743
pmcid: 5395118
doi: 10.3324/haematol.2016.153841
Hathi, D., Zhou, H., Bollerman-Nowlis, A., Shokeen, M. & Akers, W. J. Noninvasive imaging of multiple myeloma using near infrared fluorescent molecular probe. Rep. Markers Dyes Nanoparticles Mol. Probes. Biomed. Appl. VIII 723, 972304–972304 (2016).
Akers, W., Lesage, F., Holten, D. & Achilefu, S. In vivo resolution of multiexponential decays of multiple near-infrared molecular probes by fluorescence lifetime-gated whole-body time-resolved diffuse optical imaging. Mol. Imaging. 6, 237–246 (2007).
pubmed: 17711779
doi: 10.2310/7290.2007.00020
Berezin, M. Y. et al. Engineering NIR dyes for fluorescent lifetime contrast. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2009, 114–117 (2009).
Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102, 15545–15550 (2005).
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Liberzon, A. et al. Molecular signatures database (MSigDB) 30. Bioinformatics 7, 1739–1740 (2011).
doi: 10.1093/bioinformatics/btr260